Professional Documents
Culture Documents
06 Ra Peripartum Cardiomyopathy PDF
06 Ra Peripartum Cardiomyopathy PDF
Review Article
Peripartum Cardiomyopathy
VN Mishra*, Nalini Mishra**, Devanshi***
Abstract
Peripartum cardiomyopathy (PPCM) is a rare type of cardiomyopathy of unknown aetiology associated with
significant mortality and morbidity and characterized by heart failure in late pregnancy or puerperium. Recently
PPCM workshop committee has recommended inclusion of echocardiographic features of LV dysfunction to
redefine PPCM. Subsequent pregnancies are associated with a very high mortality in these patients and hence
should be avoided. Women with PPCM continue to have significant mortality despite the use of conventional
drugs for managing heart failure. Use of newer drugs such as immunoglobulin, pentoxifylline, bromocriptine,
and cabergoline along with newer interventions such as plasmapheresis, immunoadsorption, ventricular assist
devices and last but not the least the heart transplantation hold promise for future.
The serum from patients with peripartum cardiomyopathy has present with symptoms of heart failure by the end of the second
been found to contain autoantibodies in high titers, which are not trimester. Absence of cardiac symptoms in PPCM until the
present in serum from patients with idiopathic cardiomyopathy. postpartum period argues against the “latent cardiomyopathy”
Most of these antibodies are against normal human cardiac theory.
tissue proteins of 37, 33, and 25 kD. Multiparity is a risk factor
for the development of this disorder, suggesting that previous Pathological Changes
exposure to foetal or paternal antigen may elicit an abnormal In a patient of PPCM after post mortem the heart specimen
myocardial inflammatory response. The timing of presentation appear pale, soft, dilated and heavier in comparison to normal
in the immediate postpartum period supports an autoimmune heart. Cardiac chambers quite often show mural thrombi, Gray
pathogenesis.13 Adaptive changes in the maternal immune white patches of endocardial thickening are usually seen at
system allow the foetal tolerance necessary for successful the site of mural thrombi. Heart valves and coronary arteries
pregnancy and include the induction of suppressor cells. These appear normal, pericardial effusion is occasionally seen. On
adaptive changes likely underlie the clinical observation that histopathological examination evidence of degeneration, fibrosis,
autoimmune disorders such as multiple sclerosis which affect interstitial oedema, and fatty and mononuclear cell infiltration
women during their reproductive years typically have lower along with sparse or abundant collection of eosinophils in
relapse rates during pregnancy itself, with a marked increase myocardium is seen, myocardial hypertrophy is also found
in the immediate postpartum period. The majority of cases of in some patients. Electron microscopy reveals varying degree
peripartum cardiomyopathy present in early postpartum period of enlargement, destruction or fragmentation of myofibrils,
of the same pregnancy during which the restoration of the increase in size and number of mitochondria, along with the
maternal immune system results in an increase in autoimmune deposition of glycogen and some abnormal proteinacious
exacerbations in other disorders. material.19 On histochemical examination of myocardial cells,
Apoptosis and inflammation : Apoptosis (programmed cell the most important observation is the presence of sarcoplasmic
death) of cardiac myocytes occurs in heart failure and may fat vacuoles containing triglyceride without any increase of the
contribute to progressive myocardial dysfunction. Experiments lipofuscin or amyloid. Besides these, the low levels of plasma
in mice suggest that apoptosis of cardiac myocytes has a role in albumin and pre albumin, selenium and zinc have also been
peripartum cardiomyopathy. Plasma levels of C-reactive protein observed as mentioned earlier.20
and tumour necrosis factor alpha (markers of inflammation) were
found to be elevated and correlated with higher left ventricular Clinical Features
dimensions and lower left ventricular ejection fractions at
Symptoms of PPCM are the same as in patients with
presentation. Recent studies have indicated that increased
systolic dysfunction who are not pregnant. New or rapid
proteolytic cathepsin D activity in cardiomyocyte result in
onset of the following symptoms require prompt evaluation:
16kDa prolactin fragment with anti-angiogenic and apoptotic
cough, orthopnea, paroxysmal nocturnal dyspnoea, fatigue,
properties which may contribute to development of this disease.14
palpitations, weight gain, haemoptysis, chest pain, and
Pharmacological blockade of prolactin might emerge as a novel
unexplained abdominal pain. Physical examination often reveals
disease specific therapeutic option in near future.15 Another
enlarged heart, tachycardia, and decreased pulse oximetry. Blood
observation that there is elevation in the concentration of the
pressure may be normal, elevated jugular venous pressure, third
inflammatory cytokines such as tumour necrosis factor-alpha
heart sound, and loud pulmonic component of the second heart
in post partum period has been attributed as a causative factor
sound are usually found, mitral and/or tricuspid regurgitation,
by some workers.16
and pulmonary rales are also noted. Worsening of peripheral
An abnormal hemodynamic response : during pregnancy blood oedema, ascites and hepatomegaly are quite often seen.
volume and cardiac output increases. In addition the after load Arrhythmias are commonly found which may be responsible
decreases because of the relaxation of vascular smooth muscle. for embolic phenomenon peripheral or pulmonary. In some
The increase in volume and cardiac output causes transient and patients small to moderate pericardial effusion may be found.
reversible hypertrophy of the left ventricle to meet the needs Presence of elevated blood pressures (systolic >140 mm Hg and/
of the mother and foetus. The transient left ventricular systolic or diastolic >90 mm Hg) and proteinuria suggests preeclampsia.
dysfunction during the third trimester and early postpartum Overall clinical presentation and hemodynamic changes are
period returns to baseline once the cardiac output decreases,17 indistinguishable from those found in other forms of dilated
given the hemodynamic stress decompensation usually occurs cardiomyopathy.21 Few patients with high output heart failure
during pregnancy in women with previous subclinical ischemic have also been reported.22
or myopathic heart disease in last trimester of pregnancy but
in cases of PPCM because of some unknown familial, genetic Diagnosis
or environmental factors this decompensation starts late in
gestation and in more than 75% cases it is diagnosed only during Diagnosis of PPCM requires a very high level of suspicion
post partum period,18 but the same argument stands against this by treating physicians and obstetrician.They should consider
theory as well. peripartum cardiomyopathy in any peripartum patient with
unexplained symptoms of heart failure.The greatest dilemma is
Latent idiopathic Cardiomyopathy : According to this theory the lack of specific clinical criteria allowing distinction between
unmasking of latent idiopathic dilated cardiomyopathy is PPCM presenting with the new onset heart failure and other
brought to fruition by the hemodynamic stresses of pregnancy. causes of systolic dysfunction.Therefore all other possible causes
Hypertension during pregnancy, and pre-eclampsia, are both of dilated heart with heart failure must be thoroughly excluded
reported in a higher frequency in women with peripartum before accepting clinical diagnosis of PPCM.
cardiomyopathy and support that hemodynamic stresses may
play a role. However keeping the normal hemodynamic changes
of pregnancy in mind, it is well known that most women with
Lab Investigations
compromised cardiac function such as valvular heart disease X-ray chest : may reveal cardiomegaly and pulmonary venous
and foetal distress.28 Calcium channel blockers were not ventricular function recovers, the risk of serious arrhythmic
used earlier because of fear of negative contractile effects event is markedly diminished and amiodarone therapy can be
and potential risk of uterine hypoperfusion but recently discontinued. For patients with asymptomatic non-sustained
Amlodepine has been found to improve survival in non ventricular tachyarrhythmia we should not initiate amiodarone
ischemic Cardiomyopathy patients.29 Beta-blockers have therapy, but focus on correction of metabolic abnormalities and
strong evidence of efficacy in patients with heart failure, but consider the addition of a beta receptor antagonist if not already
they have not been tested in peripartum cardiomyopathy. being utilized.
Nevertheless, beta-blockers have long been used in pregnant
women with hypertension without any known adverse Newer Treatment Modalities
effects on the foetus, and patients taking these agents prior Pentoxifylline : Treatment with pentoxifylline, a xanthine
to diagnosis can continue to use them safely. derived agent known to inhibit the production of tumour
B. During Post Partum period- Treatment is identical to that necrosis factor alpha, has been shown to improve functional class
for nonpregnant women with dilated Cardiomyopathy. and left ventricular function in patients with idiopathic dilated
ACE inhibitors and ARBs are useful. The usual target dose cardiomyopathy. Similar to other aetiologies of left ventricular
is one half the maximum antihypertensive doses. Diuretics dysfunction, elevated levels of TNF alpha has been found in
are given for symptomatic relief; spironolactone or digoxin these patients.33
is used in patients who have New York Heart Association Role of Bromocriptine and Cabergoline : Most recently few
class III or IV symptoms. The dose of spironolactone is 25 studies have suggested the role of prolactin breakdown products
mg/day after dosing of other drugs is maximized. The goal in the aetiology of PPCM. Prolactin secretion can be reduced with
with digoxin therapy is the lowest daily dose to obtain a bromocriptine which had beneficial effects in a small study.34 In
detectable serum digoxin level, which should be kept at one case study with use of cabergoline which is a strong and long
less than 1.0 ng/ml, Beta-blockers are recommended as they lasting antagonist of prolactin significant improvement in left
improve symptoms, ejection fraction, and survival. Non ventricular functions were reported.35 It is premature to comment
selective beta-blockers such as carvedilol and selective ones about usefulness of these drugs at present but it seems that they
such as metoprolol have shown benefit. The goal dosage is might become important treatment modality in management of
carvedilol 25 mg twice a day or metoprolol 100 mg once a PPCM in times to come.
day.
Immune Modulating Therapy : Given the inflammatory nature
Anticoagulant Therapy of peripartum cardiomyopathy and the occasional appearance
of myocarditis on endomyocardial biopsy, immunosuppressive
Due to high risk of venous and arterial thrombosis and immune modulatory therapy has been utilized. Intravenous
anticoagulation with subcutaneous heparin should be instituted immunoglobulin improved the ejection fraction in several
in these patients more so in bedridden patients, those with studies and also markedly reduced the levels of inflammatory
LVEF <35%, presence of atrial fibrillation, mural thrombi, cytokines.36 Plasmapharesis has also been utilized effectively
obese patients and those with history of thromboembolism. for this purpose, and may be an alternative to immune globulin
Hypercoagulable state of pregnancy coupled with stasis of blood therapy in peripartum cardiomyopathy. Recently a small
due to ventricular dysfunction makes PPCM patients prone for controlled study of immunoadsorption therapy in idiopathic
thrombus formation. This situation may persists up to six weeks dilated cardiomyopathy demonstrated significant improvements
after postpartum, hence use of heparin is advocated in ante in left ventricular function, suggesting that therapies directed
partum period and that of heparin or warfarin in the post partum against humoral autoimmunity may have a significant role
period, as warfarin is contraindicated in pregnancy because of in the treatment of this disorders. Other proposed therapies
it’s teratogenic effect while use of both heparin and warfarin is which might be useful are calcium channel antagonists, statins,
safe in lactation.30 Patients with evidence of systemic embolism, monoclonal antibodies and interferon beta.
with severe left ventricular dysfunction or documented cardiac
Other Interventions and Devices : Because the disease is
thrombosis, should receive anticoagulation. Anticoagulation
reversible in good number of patients, the temporary use of
should be continued until return of normal left ventricular
an intraaortic balloon pump or left ventricular assist devices
function is documented.
may help in stabilizing critical patients.37 Extracorporeal
membrane oxygenation has been tried successfully in some
Antiarrhythmic Drugs patients as a bridge to recovery.38 Ventricular tachycardia
As in other forms of non-ischemic dilated cardiomyopathy, leading to cardiac arrest has been reported in PPCM patients,39
ventricular arrhythmias can be an important clinical issue. No to avoid such situation increasing use of automated implantable
antiarrhythmic agent is completely safe during pregnancy cardioverter defibrillator (AICD) is being tried.40 In extreme
quinidine and procainamide should be tried first because of their situations multiorgan support systems such as ventilator
higher safety profile.31 Beta blockers may be useful, for atrial therapy, continuous venovenous hemodialysis may be
arrhythmias digoxin may be considered.32 Patients presenting required besides circulatory assist devices. Plasmapharesis and
with sudden death or ventricular tachycardia with hemodynamic immunoadsosorption therapies are other newer techniques
compromise, strong consideration of an implantable cardioverter which have been tried for immunomodulation in these patients.
defibrillator (ICD) is warranted due to the potential for a fatal
Cardiac transplantation : Patients with severe heart failure
recurrence. For patients presenting with symptomatic ventricular
who does not respond despite maximal drug therapy may
tachyarrhythmia which are hemodynamically well tolerated,
be considered for cardiac transplantation to survive because
management can be tempered somewhat by the potential
of high risk of mortality. Two reports comparing results of
transient nature of the myopathy and amiodarone therapy at
cardiac transplantation in age matched females with peripartum
200 to 400 mg orally every six hourly is an alternative. If left
cardiomyopathy and idiopathic cardiomyopathy showed
favourable and comparable long term survival in both the during follow-up, subsequent pregnancies carry a high risk of
groups.41,42 However, as fewer than 3,000 hearts are available left ventricular deterioration and progressive heart failure, and
for transplantation worldwide per year this procedure remains hence pregnancy is strongly discouraged given the possible risk
more of a theoretical consideration rather than a day to day to the life of the mother. Mortality was reported to be in the range
treatment option. of 8 to 17 percent in a large study in this group in comparison
Managing hemodynamic stress of delivery for patients to 0 to 2% in patients with normal left ventricular ejection
presenting during the late stages of pregnancy, due consideration fraction before the subsequent pregnancy.45 Real problem lies
should be given to limiting the hemodynamic stress of the in the issue of how to advice 70 to 80% of women who seem to
delivery. Compensated patients may undergo vaginal delivery have a complete recovery of left ventricular size and function
with appropriate monitoring. For those patients late in following PPCM. In an attempt to clarify the prognosis in these
pregnancy with more significant hemodynamic compromise, cases, women with a history of PPCM underwent a dobutamine
elective caesarean with invasive hemodynamic monitoring of stress echocardiography test to assess their left ventricular
the mother should be considered. Single shot spinal anaesthesia contractile reserve (Lampert et al 1997).46 The results of this study
is currently not preferred because of severe consequences like indicated that women with recovered PPCM has significantly
cardiac arrest and pulmonary oedema. Controlled epidural less left ventricular contractility reserve than a group of normal
analgesia (ER) is a safe and effective method in this situation.43 matched controls. These finding are of concern and indicate a
possible though small risk in women with apparently recovered
Follow-Up Management left ventricular function. They should be explained duly during
counselling. A recent large retrospective survey suggests
Patients who show normal left ventricular function that in women with normal ejection fractions at the time of
on echocardiographic evaluation at rest or with low-dose subsequent pregnancy, there was an approximate 21% risk of
dobutamine stress test can be allowed to taper and then the development of heart failure, and a drop in the mean ejection
discontinue heart failure treatment in 6 to 12 months. They are fraction from 0.56 to 0.49. However no serious complications
encouraged to remain as active as their functional status allows, were noted and the majority of these women had a successful
however aerobic activities and heavy lifting are discouraged for delivery at term with close and careful monitoring. This was in
at least the first six months postpartum. Given the metabolic marked contrast to the women with persistent LV dysfunction
demands of lactation, breast feeding is strongly discouraged in prior to pregnancy in which 19% mortality was reported. 47
more symptomatic patients. As pharmacologic therapy to the Overall recommendation clearly being that pregnancy is avoided
patient can be passed on to the child in breast milk discouraging in women with persistent poor left ventricular function. Women
the breast feeding in more functional patients. If breastfeeding is whose LV function normalizes should still be made aware of the
considered in these women, it has to be with careful monitoring risk of possible recurrence, dobutamine stress test should be
of the baby. Echocardiogram should be repeated at 6 months post performed and due counselling should be performed though
delivery. For those patients with persistent cardiomyopathy beta in the majority of these women successful pregnancy can be
blockers may be added at this point if not already on therapy. accomplished with appropriate monitoring.
Prognosis Conclusion
Although peripartum cardiomyopathy shares many features Peripartum cardiomyopathy is an uncommon but potential life
of other forms of dilated cardiomyopathy, an important threatening cardiac failure of unknown aetiology, encountered
distinction is that women with this disorder have a much late in pregnancy or in the post partum period. Diagnosis of PPCM
higher rate of spontaneous recovery of left ventricular function should essentially include echocardiographic substantiation of
on echocardiography in post partum period; nearly half of the left ventricular dysfunction. Role of endomyocardial biopsy in
women will normalize their ejection fraction during follow-up day to day diagnosis is controversial. Usefulness of diuretics,
within six months. Prognosis is directly correlated to recovery vasodilators, digoxin, beta blockers and anticoagulant in medical
of left ventricular function. For those women whose LVEF management is well established. ACE inhibitors and ARB
normalizes during follow-up, the prognosis is excellent as blockers should be avoided during pregnancy but should be
without the stimulus of a subsequent pregnancy the chance of started in post partum period. In resistant cases pentoxifylline,
development of heart failure or future LV dysfunction is minimal. immunoglobulin and immunosuppressive drugs may be used.
For those women whose left ventricular function does not Bromocriptine and cabergoline hold promise for the future.
recover, prognosis remains guarded and mortality rates as high Severe cases might require advanced life support systems and
as 10-50% has been reported.44 LV size is an important predictor, even heart transplantation. Prognosis is linked to recovery
as women presenting without significant LV dilatation appeared of left ventricular functions. Subsequent pregnancies are
to have a greater chance of spontaneous recovery during follow- associated with a very high mortality more so in those whose
up. In contrast, women with marked LV dilatation at presentation LV functions do not improve even six month after puerperium
appeared to have a greater likelihood of developing into a hence pregnancy should be avoided in this group. In patients
chronic cardiomyopathy. Initial NYHA class or hemodynamic with normal cardiac function on echo evaluation subsequent
status does not seem to predict the likelihood of subsequent pregnancy may be considered under close multidisciplinary
recovery. A fractional shortening on echocardiogram less than supervision.
20% and a LV end diastolic dimension greater than or equal to
6 cm was associated with a threefold increase in persistent LV References
dysfunction. 1. Pearson GD, Veille JC, Rahimttola S, et al. Peripartum
Cardiomyopathy; National Heart, Lung and Blood Institute and
Risks of Subsequent Pregnancies Office of Rare Diseases (National Institute of Health) workshop
In patients whose left ventricular function fails to normalize recommendation and review. JAMA 2000;283:1183-88.
2. Selle T, Renger I, Labidi S et al; Reviewing peripartum 25. AvillaWS, de Carvalho MEC, Tschaen CK et al; Pregnancy and
Cardiomyopathy; current state of knowledge. Future Cardiol peripartum Cardiomyopathy; A comparative and prospective
2009;5:175-89. study. Arq Brasss Cardiol 2002;9:484-93.
3. Pandit V, Shetty S, Kumar A et al; Incidence and out come of 26. Desai P; Peripartum Cardiomyopathy; A review. J of Obstetrics and
peripartum Cardiomyopathy from a tertiary hospitalin South India. Gynecology of India 2010;60:25-32.
Trop Doct 2009;39:168-9. 27. Shotan A, Widerhorn J,Hurst A et al; Risks of angioyensin
4. Desai D, Moodley J, Naidoo D; Peripartum Cardiomyopathy converting enzyme inhibition during pregnancy: Experimental and
Experience at king Edward VIII Hosp, Durban, South Africa and clinical evidence , potential mechanism and recommendations for
a review of the literature. Trop Doct 1995;25:118 23. use. Am J Med 1994;96:451.
5. Fett JD, Christie LJ, Carraway RD et al; Five year prospective study 28. Sliwa K, Fett J, Elkayam U; Peripartum Cardiomyopathy. Lancet
of the incidence and prognosis of the peripartum cardiomyopathy 2006;368:687-693.
at a single institution. Mayo Clinic Proc 2005;80:1602-6. 29. Packer M, O’Connor CM, Ghali JK et al; Effects of Amlodepine on
6. Sanderson JE,Adesanya CO, Anjorin FIet al; Postpartum cardiac morbidity and mortality in severe chronic heart failure.Prospective
failure- heart failure due to volume over load? Am Heart J Randomized Amlodepine Survival Evaluation Study Group. N Eng
1979;97:613-621. J Med 1996;335:1107-1114.
7. Shamiri MQ, Nozha MM; Peripartum cardiomyopathy: Searching 30. Bates GM, Greer IA, Hirsh J et al; Use of antithrombotic agents
for a better understanding. Saudi Med J 2003;24:1048-51. during pregnancy; the seventh ACCP conference on Antithrombotic
8. Tummala PP, Rao KS, Akhter MW et al; Peripartum cardiomyopathy. and Thrombolytic therapy. Chest 2004;126:627S- 644S.
Clinical profile of 100 patients diagnosed in the United States. 31. Page RL; Treatment of arrhythmias during pregnancy. Am Heart J
Circulation 1999;100: I579. 1995;130:871-6.
9. Demakis JG, Rahimtoola SH; Peripartum Cardiomyopathy. 32. Ray P, Murphy GJ, Shutt LE; Recognition and management of
Circulation 1971;44;964-68. maternal cardiac disease in pregnancy. Br J Anesth 2004;93:428-39.
10. Cenac A, Simonoff M, Moretto P et al; Low plasma selenium is a 33. Silwa K, Skudicky D, Candy G et al; The addition of pentoxifylline
risk factor for peripartum cardiomyopathy. A comparative study to conventional therapy improves outcome in patients with
in Sahelian Africa. Int J Cardiol 1992;36:57-9. peripartum cardiomyopathy. Eur J Heart Fail 2002;4:305-9.
11. Rizeg MN, Rickembacher PR, Fowler MB et al; Incidence of 34. Jahns BG, Stein W, Hilfiker-Kleiner D et al; Peripartum
myocarditis in peripartum cardiomyopathy. Am J Cardiol cardiomyopathy- a new treatment option by inhibition of prolactin
1994;74:474. secretion. Am J Obstet Gynecol 2008;199;5-6.
12. Felker GM, Thomson R,Hare JM et al. Underlying causes 35. de Jong JS, Rietveld K, van Lochem LT et al; Rapid left ventricular
and long term survival in patients with initially unexplained recovery after cabergoline treatment in a patient with peripartum
cardiomyopathy. N Engl J Med 2000;342:1077-84. cardiomyopathy. Eur J Heart Fail 2009;11:220-2.
13. Bahloul M, Ben Ahmed MN, Laaroussi L et al. Peripartum 36. Bozkurt B, Villaneuva FS, Halubkov R et al; Intravenous
Cardiomyopathy; Incidence, Pathogenesis, diagnosis, treatment immunoglobulin in the therapy of peripartum cardiomyopathy. J
and prognosis. Ann FR Anesth Renaim 2009;28:44-60. Am Coll Cardiol 1999;34:177-180.
14. Kielgast UL, Schierbeck L, Diimcke C et al; Peripartum 37. Hovsepian PG, Ganzel B, Sohi GS et al; Peripartum cardiomyopathy
Cardiomyopathy in an obese pregnant woman. Ugeskr Laeger treated with a left ventricular assist device as a bridge to cardiac
2009;171:2487-9. transplantation. South Med J 1989;82:527.
15. Reuwer AQ, Reuwer PJ, Vander Post JA,et al; Prolactin 38. Palanzo DA, Baer LD, EL- Banayosy A et al; Successful treatment
fragmentation by trophoblastic matrix metalloproteinase as a of peripartum cardiomyopathy with extracorporeal membrane
possible contributor to peripartum cardiomyopathy and pre- oxygenation. Perfusion 2009;24:75-9.
eclampsia. Medical Hypothesis 2009. 39. Yahagi N, Kumon K, Nakatani T et al; Peripartum cardiomyopathy
16. Silwa K, Forster O, Zhanje F et al; Outcome of subsequent pregnancy and tachycardia followed by multiple organ failure. Anesth Analg
in patients with documented peripartum cardiomyopathy. Am J 1994;79:581-2.
Cardiol 2004;93:1441-3. 40. Elkayam U, Akhter MW Singh H et al; Pregnancy associated
17. Clark SL, Cotton DB, Lee W et al; Central hemodynamic assessment cardiomyopathy: clinical characterstics and a comparison between
of normal term pregnancy. Am J Obstet Gynecol 1989;161:1439-42. early and late presentation. Circulation 2005;111:2050- 5.
18. Homans DC: al; Peripartum Cardiomyopathy. N Eng J Med 41. Keogh A, McDonald P, SprattP, et al; Outcome in peripartum
1985;312:1432-7. cardiomyopathy after heart transplantation. J Heart Lung Transplant
19. O’Connell JB, Costanzo Nordin MR, Subramanian et al; Peripartum 1994;13:202-207.
Cardiomyopathy; Clinical, hemodynamic, histological and 42. Peter R, Rickenbacher MD; Long term outcome after heart
prognostic characterstics. J Am Coll Cardiol 1986;8:52-56. transplantation for peripartum cardiomyopathy. Am Heart J
20. Veille JC,Zaccaro D; Peripartum Cardiomyopathy; summary of an 1994;127:1318-23.
international surveyon peripartum Cardiomyopathy. Am J Obstet 43. Witlin AG, Mabie WC, Sibai BM. Peripartum cardiomyopathy; an
Gynaecol 1999;181:315-19. ominous diagnosis. Am J Obstet Gynecol 1997;176:182-8.
21. Van Hoevan KH, Kitsis RN, Katz SD et al; Peripartum versus 44. Ro A, Frishman Wh. Peripartum cardiomyopathy. Cardiol Rev
idiopathic dilated cardiomyopathy in young women- a comparisons 2006;14:35-42.
of clinical pathological and prognostic features. Int J Cardiol 45. Tummala PP, Akhter MW, Hameed AB,et al; Risk of subsequent
1993;40:57. pregnancies in women with a history of peripartum cardiomyopathy.
22. Martin Neto JA, Maciel BC, Teran Urbanetz LL et al; High output Circulation 1999;100:381.
failure in patients with peripartum cardiomyopathy. A comparative 46. Lampert BM, Weinert L, Hibbard, et al; Contactile reserve in patients
study with dilated cardiomyopathy. Am Heart J 1990;121:134. with peripartum cardiomyopathy and recovered left ventricular
23. Braunwald ZL; Heart Diseases; A textbook of cardiovascular function. Am J Obst Gyne 1997;176:189-95.
medicine. HIE Saunders, 8th edition, 65;2179-81. 47. Elkayam MD, Tummala PP, Rao K, et al. Maternal and foetal
24. Duran N, Giines H, Duran et Predictors of prognosis in patients with outcomes of subsequent pregnancies in women with peripartum
peripartum cardiomyopathy. Int J Gynaecol Obstet 2008;101:137-40. cardiomyopathy. N Engl J of Med 2001;344:1567-71.